Other
Income Taxes Receivable Noncurrent
Moderna Income Taxes Receivable Noncurrent remained flat by 0.0% to $161M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 62.6%, from $99M to $161M.
Analysis
StatementBalance Sheet Statement
SectionOther
First reportedQ4 2024
Last reportedQ1 2026May 1, 2026
Metric ID:
other_income_taxes_receivable_noncurrentHistorical Data
6 periods
| Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | $97M | $99M | $99M | $99M | $161M | $161M |
| QoQ Change | — | +2.1% | +0.0% | +0.0% | +62.6% | +0.0% |
| YoY Change | — | — | — | — | +66.0% | +62.6% |
Range$97M – $161M
CAGR+50.0%
Avg YoY Growth+64.3%
Median YoY Growth+64.3%
Current Streak5+ quarters growth
Income Taxes Receivable Noncurrent at Other Companies
Frequently Asked Questions
- What is Moderna's income taxes receivable noncurrent?
- Moderna (MRNA) reported income taxes receivable noncurrent of $161M in Q1 2026.
- How has Moderna's income taxes receivable noncurrent changed year-over-year?
- Moderna's income taxes receivable noncurrent increased by 62.6% year-over-year, from $99M to $161M.